Richard Pollock on LinkedIn
Curriculum Vitae

Health Economist

Personal details

Richard Pollock, originally from Huddersfield, UK. Studied Natural Sciences at the University of Cambridge. Currently working as a senior health economist for Covalence Research Ltd in Washington DC, USA.

close
Image from Wikipedia (GNU license)Basel-Stadt Canton WebsiteMap of Basel

Professional experience

Currently employed by Covalence Research Ltd (December 2018 onwards). Responsibilities include:

  • Systematic literature review and meta-analysis (using Sourcerer, R and Review Manager)
  • Preparation of global value and reimbursement dossiers
  • Development of budget impact models and analyses for local, regional or national reimbursement
  • Cost-effectiveness analysis, including state transition Markov modelling and discrete event simulation using a variety of software tools, including R, Python, Treeage Pro and Berkeley Madonna
  • Pharmacoeconomic analysis and write-up for formulary approval
  • Business case model development
  • Clinical commissioning evidence summary development

Peer-reviewer for Diabetologia, the Journal of Medical Economics, Diabetes Research and Clinical Practice, Expert Review of Pharmacoeconomics & Outcomes Research and Biosimilars.

Lead developer of the PRIME Diabetes Model, a web-based model for evaluating the cost-effectiveness of interventions for type 1 and type 2 diabetes.

Previously employed by Ossian Health Economics and Communications GmbH as a senior health economist (February 2009 to November 2018), and IMS Health as a health economics and outcomes research analyst (February 2008 to January 2009).

Peer-reviewed publications

Published

  • Brennan VK, Colaone F, Shergill S, Pollock RF. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. J Med Econ. 2020.
  • Pollock RF, Brennan VK, Peters R, Paprottka PM. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020.
  • Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-weekly Semaglutide versus Dulaglutide in Japan: A Short-term Cost-effectiveness Analysis. Adv Ther. 2020; 37(10):4446-57.
  • Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2020; 146(10):2575-87.
  • Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020; 23(7):751-9.
  • Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, Bonroy K. Impact of Stigma on People Living with Chronic Hepatitis B. Patient Relat Outcome Meas. 2020; 2020(11):95-107.
  • Pollock RF, Colaone F, Guardiola L, Shergill S, Brennan VK. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. J Med Econ. 2020; 23(6):593-602.
    • Manuscript featured in Pharmaco­Economics & Outcomes News article “Cost implications of different IV iron formulations in an iron infusion clinic”, February 2020; 847:7.
  • Loughnane F, Muduma G, Pollock RF. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. Adv Ther. 2020; 37(3):1218-1232.
  • Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Exp Rev Hematol. 2020; 13(2):187-95.
  • Vogelberg C, Hamelmann E, Wahn U, Domdey A, Pollock RF, Grand TS. Cost-Effectiveness Of The SQ® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective. Clinicoecon Outcomes Res. 2019; 11:637-49.
    • Manuscript featured in Pharmaco­Economics & Outcomes News article “Insulin degludec good value for money in T2DM with high CV risk”, July 2019; 832:17.
  • Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy. 2019; 17(5):615-27.
  • Gæde P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Ther. 2019; 10(4):1297-317.
  • Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B; on behalf of the DEVOTE Study Group. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events – a Canadian setting (DEVOTE 9). Diabetes Obes Metab. 2019; 21(7):1706-1714.
  • Johansen P, Hunt B, Iyer NN, Dang-Tan T, Pollock RF. Achieving HbA1c treatment targets and weight loss with once-weekly semaglutide versus exenatide extended-release and dulaglutide: A cost of control analysis in the USA. Adv Ther. 2019; 36(5):1190-9.
  • Pollock RF, Muduma G. A Systematic Literature Review and Indirect Comparison of Iron Isomaltoside and Ferric Carboxymaltose in Iron Deficiency Anaemia After Failure or Intolerance of Oral Iron Treatment. Expert Rev Hematol. 2019; 12(2):129-36.
  • Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A Cost-Utility Analysis of Dulaglutide Versus Insulin Glargine as Third-line Therapy for Type 2 Diabetes in Canada. J Comp Eff Res. 2019; 8(4):229-40.
    • Manuscript featured in IBD News Today and in Pharmaco­Economics & Outcomes News article “Switch from Ferinject to Monofer reduces infusions and costs”, December 2018; 818:29.
  • Pollock RF, Muduma G. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Adv Ther. 2018; 35(12):2128-37.
  • Pollock RF, Chubb B, Valentine WJ, Heller S. Evaluating the Cost-Effectiveness of Insulin Detemir versus NPH Insulin in Patients with Type 1 or Type 2 Diabetes in the UK Using a Short-term Modeling Approach. Diabetes Metab Syndr Obes. 2018; 11:217-26.
  • Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB. DEVOTE 5: Evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal-bolus regimens for type 2 diabetes in the UK. Diabetes Ther. 2018; 9(3):1217-32.
  • Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brändle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM; for The Mount Hood Challenge Modelling Group. Computer Modelling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value Health. 2018; 21(6):724-31.
  • Pollock RF, Meckley L. An Evaluation of the Budget Impact of A New 20% Subcutaneous Immunoglobulin (Ig20Gly) For The Management Of Primary Immunodeficiency Diseases In Switzerland. Clinicoecon Outcomes Res. 2018; 10:223-9.
  • Wilkinson L, Hunt B, Johansen P, Iyer NN, Dang-Tan T, Pollock RF. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Ther. 2018; 9(3):951-61.
    • Manuscript featured in Pharmaco­Economics & Outcomes News article “Rapid-acting insulin analogue cost effective in Germany”. March 2018; 799:32.
  • Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating Type 1 Diabetes with a Rapid-acting Analog Insulin Regimen versus Regular Human Insulin in Germany: A Long-term Cost-effectiveness Evaluation. Appl Health Econ Health Policy. 2018; 16(3):357-66.
  • Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early after Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Ther. 2018; 9(1):87-99.
  • Lane W, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ. 2018; 21(2):144-51.
  • Pollock RF, Muduma G. Intravenous Iron Treatments for Iron Deficiency Anemia in Inflammatory Bowel Disease: A Budget Impact Analysis of Iron Isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017; 14(12):1439-46.
  • Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clinicoecon Outcomes Res. 2017; 9:475-83.
    • Cover story in October 2017 Anesthesiology News: "Meta-Analysis Confirms Capnography Monitoring Advantageous"
  • Saunders R, Struys MMRF, Pollock RF, Mestek M, Lightdale JR. Patient safety during procedural sedation using capnography monitoring: A systematic review and meta-analysis. BMJ Open. 2017; 7:e013402.
  • Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye KS. The PRIME Diabetes Model: Novel Methods for Estimating Long-term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. Value Health. 2017; 20(7):985-91.
  • Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine in patients with type 1 or type 2 diabetes in Denmark. J Med Econ. 2017; 20(3):213-20.
  • Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS ONE. 2016; 11(11):e0160421.
  • Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. J Med Econ. 2016; 19(10):995-1002.
  • Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. J Med Econ. 2016; 19(7):672-83.
  • Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Adv Ther. 2016; 33(3):345-56.
  • Muduma G, Odeyemi I, Pollock RF. Evaluating the Cost-effectiveness of Prolonged-release Tacrolimus Relative to Immediate-release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs - Real World Outcomes. 2016; 3:61-8.
  • Muduma G, Odeyemi I, Pollock RF. Evaluating the Economic Implications of Nonadherence and Antibody-mediated Rejection in Renal Transplant Recipients: the Role of Once-daily Tacrolimus in the United Kingdom. J Med Econ. 2015; 18(12):1050-9.
  • Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Res Clin Pract. 2015; 109(1):95-103.
  • Pollock RF, Kappelgaard AM, Seitz L. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opin Drug Deliv. 2015; 12(3):353-60.
  • Muduma G, Odeyemi I, Pollock RF. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. J Med Econ. 2014; 17(7):520-6.
  • Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Prefer Adherence. 2014; 8:391-9.
  • Ericsson Å, Pollock RF, Hunt B, Valentine W. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013; 16(12):1442-52.
  • Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Med Devices (Auckl). 2013; 6:107-14.
  • Pollock RF, Chilcott J, Muduma G, Valentine WJ. Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. J Med Econ. 2013; 16(2):249-59.
  • Pollock RF, Muduma G, Valentine WJ. Evaluating the Cost-Effectiveness of Laparoscopic Adjustable Gastric Banding Versus Standard Medical Management in Obese Patients With Type 2 Diabetes in the UK. Diabetes Obes Metab. 2013; 15(2):121-9.
  • Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ. A UK Analysis of the Cost-Effectiveness Of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Adv Ther. 2012; 29(12):1051-66.
  • Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson Å, Valentine WJ. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. J Med Econ. 2012; 15(5):977-86.
  • Pollock RF, Curtis BH, Valentine WJ. A Long-term Analysis Evaluating the Cost-effectiveness of Biphasic Insulin Lispro Mix75/25 and Mix50/50 versus Long-acting Basal Insulin Analogs in the United States. J Med Econ. 2012; 15(4):766-75.
  • Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the Cost-Effectiveness of Reduced Mild Hypoglycemia in Subjects With Type 1 Diabetes Treated With Insulin Detemir or NPH Insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2012; 29(3):303-12.
  • Lippuner K, Pollock RF, Smith-Palmer J, Meury T, Valentine WJ. A Review of the Cost-Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Appl Health Econ Health Policy. 2011; 9(6):403-17.
  • Pollock RF, Valentine WJ, Thomsen TL, Nishimura H. Evaluating the cost-effectiveness of rapid-acting insulin aspart compared with human insulin in Japanese type 2 diabetes patients. J Med Econ. 2011; 14(1):36-46.
  • Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Long-acting insulin analogs: a review of “real-world” effectiveness in patients with type 2 diabetes. Curr Diabetes Rev. 2011; 7(1):61-74.
  • Pollock RF, Valentine WJ, Goodall G, Brändle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents: A long-term modeling study in Switzerland. Swiss Med Wkly. 2010; 140:w13103.
  • Valentine WJ, Pollock RF, Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Curr Med Res Opin. 2010; 26(6):1399-412.
  • Pollock RF, Adryan B. BioSAVE: Display of scored annotation within a sequence context. BMC Bioinformatics. 2008; 9:157.
    • Show earlier publications

Accepted

  • Pollock RF, Brennan VK, Shergill S, Colaone F. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Rev Anticancer Ther. 2020.

Conference proceedings

2020

  • Pollock RF, Muduma G. An Economic Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in the Nordics: Norway, Sweden, and Finland. Abstract and poster presentation PSY9 at Virtual ISPOR Europe 2020.
  • Brennan VK, Colaone F, Shergill S, Pollock RF. SIR-Spheres Y-90 Resin Microspheres Versus Best Supportive Care in the Treatment of Unresectable Metastatic Colorectal Cancer Refractory to Chemotherapy: A Cost-Utility Analysis in the UK. Abstract and poster presentation PCN123 at Virtual ISPOR Europe 2020.
  • Valentine WJ, Norrbacka K, Boye K, Osumili B, Pollock RF. The PRIME Type 2 Diabetes Model: A New, Product-independent Model to Evaluate Long-term Clinical and Cost Outcomes in Type 2 Diabetes. Abstract and poster presentation PDB34 at Virtual ISPOR Europe 2020.
  • Kabiru DK, Maw F, Johnson M, Dhar A, Pollock RF. Resource Utilization and Costs Associated With Intravenous Iron Infusions in Patients With Inflammatory Bowel Disease and Iron Deficiency Anemia or Hypoferritinemia: Real-world Evidence from the UK. Abstract and poster presentation P1485 at UEG Week 2020.
  • Pollock RF, Brennan VK, Peters R, Paprottka PM. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Abstract and presentation at CIRSE 2020, Münich, Germany, 2020.
  • Pollock RF, Valentine WJ. Using Global Patient-Level Simulation Models to Conduct Cost-Utility Analyses Tailored to the United States: A Case Study with the PRIME Diabetes Model in Type 1 Diabetes. Abstract and poster presentation at the 9th Conference of the American Society of Health Economists, St. Louis, USA, 2020.
  • Pollock RF, Muduma G. A Patient-level Cost-effectiveness Analysis of Iron Isomaltoside Versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia in the United Kingdom. Abstract and poster presentation PSY14 at ISPOR 2020, Orlando, USA, 2020.
  • Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. A Systematic Review and Exploratory Network Meta-analysis of Third-line Treatments for Metastatic Colorectal Cancer. Abstract and poster presentation PCN40 at ISPOR 2020, Orlando, USA, 2020.
  • Pollock RF, Valentine WJ. A Cost-utility Analysis of Sodium-glucose Cotransporter (Sglt) 2 Inhibitors in Addition to Basal-bolus Insulin in the Treatment of Type 1 Diabetes in the usa Using the Prime Diabetes Model. Abstract and poster presentation PDB29 at ISPOR 2020, Orlando, USA, 2020.
  • Pollock R, Colaone F, Guardiola L, Shergill S, Brennan V. An economic analysis of Yttrium-90 radioembolisation versus Tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. Abstract and poster presentation 255 at ECIO 2020, Nice, France, April 26-29, 2020.

2019

  • Pollock RF, Valentine WJ. Evaluating the Cost-utility of Adding Sodium-glucose Cotransporter Inhibitors to a Basal-bolus Insulin Regimen in Patients With Type 1 Diabetes in the UK: An Analysis Using the PRIME Diabetes Model. Abstract and poster presentation PDB59 at ISPOR Europe 2019, Copenhagen, Denmark, 2019.
  • Pollock RF. Improving the Performance of Patient-level Simulation Models Using Multi-threading and Single Instruction Multiple Data (SIMD) Operations. Abstract and poster presentation PNS302 at ISPOR Europe 2019, Copenhagen, Denmark, 2019.
    • Selected as an ISPOR podium presentation in the Diabetes Studies breakout session.
  • Pollock RF, Valentine WJ. Modeling the Incidence of Microvascular Complications at Glycemic Control Targets Recommended by the American Diabetes Association for Adult Patients With Type 1 Diabetes: An Analysis Using the PRIME Diabetes Model. Abstract and podium presentation DM4 at ISPOR 2019, New Orleans, USA, 2019.
  • Pollock RF, Muduma G. A Systematic Literature Review and Indirect Comparison of Iron Isomaltoside and Ferric Carboxymaltose in Iron Deficiency Anaemia After Failure or Intolerance of Oral Iron Treatment. Abstract and poster presentation PSY4 at ISPOR 2019, New Orleans, USA, 2019.
  • Loughnane F, Pollock RF, Muduma G, Cook L. A Resource Impact Analysis of Iron Isomaltoside in the Treatment of Iron Deficiency Anemia in Ireland. Abstract and poster presentation PSY6 at ISPOR 2019, New Orleans, USA, 2019.
  • Pollock RF, Shergill S, Brennan VK, Colaone F. Using Nested Markov Models to Model the Budget Impact of Treatment Sequences in Oncology: A Worked Example in Hepatocellular Carcinoma. Abstract and poster presentation at the 8th Conference of the American Society of Health Economists, Washington DC, USA, 2019.
  • Pollock RF, Hallén N, Hoxer CS. The value of once-weekly semaglutide in bringing people with type 2 diabetes to single and composite endpoints: A UK cost of control analysis versus dulaglutide, exenatide extended-release, sitagliptin and insulin glargine U100. Abstract and poster presentation at the Diabetes UK Professional Conference 2019, Liverpool, UK, 2019.
  • Pollock RF, Parekh W, Watcham S, Hallén N. Cost impact analysis of mealtime fast-acting insulin aspart compared with insulin aspart in adults with Type 1 diabetes in the UK. Abstract and poster presentation at the Diabetes UK Professional Conference 2019, Liverpool, UK, 2019.

2018

  • Woo V, Zinman B, Pieber TR, Pollock RF, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Heller S. Short-term cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for patients with type 2 diabetes (T2D) at high risk of hypoglycemia in DEVOTE. Abstract and poster presentation at the 21st Professional Conference and Annual Meetings of the Canadian Diabetes Association, Halifax, Canada, 2018.
  • Pollock RF, Valentine WJ. Using models to generate cardiovascular risk tables for patients with diabetes: an example using the PRIME Diabetes Model. Abstract and oral presentation at the Mt Hood Diabetes Challenge 2018, Düsseldorf, 2018.
  • Pollock RF, Muduma G. An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark. Abstract and poster presentation PSY47 at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Barcelona, 2018.
  • Pollock RF, Valentine WJ. Evaluating the relationship between glycemic control, incidence of severe hypoglycemia, and long-term complication costs in patients with type 1 diabetes in the United States. Abstract and poster presentation PDB53 at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Barcelona, 2018.
  • Tikkanen CK, Johansen P, Hunt B, Malkin S, Pollock RF. Once-weekly semaglutide provides better health outcomes compared to dulaglutide as dual therapy in the treatment of type 2 diabetes: A cost-effectiveness analysis. Poster presentation at the European Association for the Study of Diabetes 54th Annual Meeting, Berlin, 2018.
  • Igarashi A, Hunt B, Pollock RF, Wilkinson L, Nakanishi R, Langer J. Lower cost of successfully treating patients with type 2 diabetes to targets with once-weekly semaglutide versus dulaglutide in Japan. Oral presentation 91539 at the 61st Annual Meeting of the Japan Diabetes Society, Tokyo, 2018.
  • Pollock RF, Johansen P, Hunt B, Iyer NN, Tan TD. Evaluation of the cost per patient achieving composite and single treatment targets with once-weekly semaglutide and exenatide ER in the United States. Abstract and poster presentation PDB49 at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, 2018.
  • Bonroy K, Smith-Palmer J, Sbarigia U, Pollock RF, Cerri K, Valentine W. The nature and impact of stigma in patients with chronic hepatits B: A systematic literature review. Abstract and poster presentation at the EASL International Liver Congress, Paris, 2018.
    • Show previous years

2017

  • Pollock RF, Hunt B, Valentine W. Evaluating the Importance of Realistically Simulating Risk Factor Progression over Time: A Health Economic Modeling Analysis in Type 1 Diabetes. Abstract and poster presentation PRM120 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Pollock RF, Valentine W. Quantifying the Trade-off Between Improved Glycemic Control and Severe Hypoglycemia Risk in Patients With Type 1 Diabetes: A Health Economic Analysis in the UK. Abstract and poster presentation PDB71 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Pollock RF, Schwartz J, Howell J, Spalding J. Evaluating the Cost-utility of Immunosuppressive Regimens in Liver Transplant Recipients in Canada. Abstract and poster presentation PHP94 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Meckley LM, Pollock RF. An Evaluation of the Budget Impact of a New 20% Subcutaneous Immunoglobulin (Ig20Gly) for the Management of Primary Immunodeficiency Diseases in Switzerland. Abstract and poster presentation PSY27 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Pollock RF, Muduma G. Intravenous Iron Treatments for Iron Deficiency Anemia in Inflammatory Bowel Disease: a Budget Impact Analysis of Iron Isomaltoside 1000 in the UK. Abstract and poster presentation PSY26 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Mezquita P, Basse A, Thorsted BL, Pollock RF, Price H. Comparison of the Long-term Cost-effectiveness of IDegLira Versus Multiple Daily Insulin Injections in the Spanish Setting Using Real-world Clinical Data. Abstract and poster presentation PDB31 at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Glasgow, 2017.
  • Pollock RF, Muduma G. A Budget Impact Analysis of Parental Iron Treatments for Iron Deficiency Anemia in the UK: Reduced Resource Utilization With Iron Isomaltoside (Monofer). Abstract and poster presentation PSY35 at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Boston, 2017.
    • Awarded ISPOR Top 10% Rosette.
  • Pollock RF, Schwartz J, Howell J. Adherence and De Novo Donor-specific Antibody Formation in Renal Transplant Recipients: Implications for Clinical and Economic Outcomes Associated With Prolonged-release and Immediate-release Tacrolimus in Canada. Abstract and poster presentation PUK18 at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Boston, 2017.
  • Lane W, Weatherall J, Gundgaard J, Pollock RF. Insulin Degludec vs. Insulin Glargine U-100 for Patients with Type 1 Diabetes in the U.S.: A Budget Impact Analysis Based on Evidence from a Randomized, Double-Blind, Crossover Trial (SWITCH 1). Abstract and poster presentation 1336-P at the American Diabetes Association 77th Scientific Sessions, San Diego, 2017.
  • Lane W, Weatherall J, Gundgaard J, Pollock RF. Insulin Degludec vs. Insulin Glargine for Patients with Type 2 Diabetes in the U.S.: A Budget Impact Analysis Based on Evidence from a Randomized, Double-Blind, Crossover Trial (SWITCH 2). Abstract and poster presentation 1337-P at the American Diabetes Association 77th Scientific Sessions, San Diego, 2017.
  • Saunders R, Lightdale JR, Pollock RF, Mestek M, Struys MMR. Does geography matter: meta-analysis of patient safety during procedural sedation with and without capnography. Abstract and poster presentation 16AP06-3 at the Euroanaesthesia 2017 Congress, Geneva, 2017.
  • Howell J, Pollock R, Schwartz J. Impact of Immunosuppression Adherence on De Novo Donor-specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis. Abstract and poster presentation at the American Transplant Congress, Chicago, 2017.

2016

  • Pollock RF, Brändle M, Valentine WJ. A covaried, target-based, patient-level model of HbA1c progression in type 1 diabetes. Abstract and oral presentation at Mt Hood Diabetes Challenge 2016, St. Gallen, 2016.
  • Saunders RJK, Lightdale JR, Pollock RF, Mestek ML, Struys MMRF. A Systematic Review and Meta-analysis of Patient Safety Outcomes During Procedural Sedation With and Without Capnography. Abstract and poster presentation at the Evidence-Based Peri-Operative Medicine Congress, London, 2016.
  • Saunders RJK, Lightdale JR, Pollock RF, Mestek ML, Struys MMRF. Systematic Review and Meta Analysis of the Effectiveness of Capnography Monitoring for Detecting Severe Oxygen Desaturation During Endoscopic Procedural Sedation. Oral presentation 463 at Digestive Disease Week, San Diego, 2016.
  • Morano R, Ruiz L, Pollock R, Hunt B, Martin A. Cost-effectiveness analysis of Albiglutide vs Sitagliptin in Type 2 Diabetes Mellitus patients in Spain. Abstract and poster presentation P-109 at the XXVII Congreso Nacional de la Sociedad Española de Diabetes, Bilbao, 2016.

2015

  • Boye KS, Lage ME, Treglia M, Lage MJ, Valentine W, Pollock RF, Saunders R. Verification and Validation of Health Economic Models for Diabetes. Abstract and poster presentation PRM109 at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, 2015.
  • Muduma G, Odeyemi I, Pollock RF. Evaluating the Cost-effectiveness of Prolonged-release Tacrolimus Relative to Immediate-release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Abstract and poster presentation PGI24 at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, 2015.
  • Muduma G, Odeyemi I, Pollock RF. A Cost-utility Analysis of Prolonged-release Tacrolimus Relative to Immediate-release Tacrolimus and Ciclosporin in Liver Transplant Recipients in the UK. Abstract and poster presentation PGI37 at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, 2015.
  • Saunders R, Boye K, Van Brunt K, Pollock R, and Valentine W. Cost-effectiveness of Rapid-acting Analog Insulin for Type 1 Diabetes in the UK Setting. Abstract and poster presentation PDB74 at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, 2015.
  • Valentine WJ, Pollock RF, Saunders R, Bae JP, Norrbacka K, Curtis BH, Boye KS. Predicting complications and long-term outcomes in type 1 diabetes: the PRIME Diabetes Model. Poster presentation 882 at the European Association for the Study of Diabetes 51st Annual Meeting, Stockholm, 2015.
  • Valentine W, Pollock R, Saunders R, Bae J, Norrbacka K, Curtis BH, Boye K. Computer Simulation Modeling of Type 1 Diabetes and Its Complications: The PRIME Diabetes Model. Abstract 2645-PO at the American Diabetes Association 75th Scientific Sessions, Boston, 2015.
  • Ruiz L, Morano R, Pollock R, Hunt B, Martin A. [Cost-effectiveness analysis of albiglutide vs insulin glargine for type 2 diabetes mellitus in Spain.] Análisis coste efectividad del tratamiento con albiglutida vs insulina glargina en pacientes con diabetes mellitus tipo 2 en España. Poster presentation P-047 at the Asociación de Economia de la Salud XXXV Jornadas de Economia de la Salud, Granada, 2015.
  • Muduma G, Odeyemi I, Pollock R. Evaluating the economic implications of nonadherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily, prolonged-release tacrolimus in the UK setting. Abstract and poster presentation PUK5 at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, 2015.
  • Muduma G, Saunders R, Odeyemi I, Pollock R. Systematic literature review, meta-analysis and indirect treatment comparison of prolonged-release tacrolimus relative to ciclosporin and immediate-release tacrolimus as the primary immunosuppressive regimen in liver transplant recipients. Abstract and poster presentation PGI3 at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, 2015.
  • Muduma G, Pollock R, Odeyemi I, Saunders R. Bayesian hierarchical modeling of randomized and non-randomized studies comparing ciclosporin with immediate- and prolonged-release tacrolimus in liver transplant recipients. Abstract and poster presentation PGI2 at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, 2015.

2014

  • Saunders R, Boye K, Bae J, Norrbacka K, Timlin L, Pollock R, Valentine W. How can we best predict cardiovascular disease risk in type 1 diabetes? A comparison of risk equations. Abstract and oral presentation A-14-691-EASD at the European Association for the Study of Diabetes 50th Annual Meeting, Vienna, 2014.
  • Kappelgaard AM, Pollock RF, Seitz L, Smith C. Small Dose Increments Allow for Accurate Dosing and Reduce Growth Hormone (GH) Wastage in GH Injection Devices. Abstract and poster presentation MON-0151 at the 16th International Congress of Endocrinology (ICE/ENDO), Chicago, 2014.

2013

  • Valentine W, Pollock R, Carr E, Aubonnet P, Mitchell P, Keech A. Evaluating the cost-utility of fenofibrate treatment of diabetic retinopathy in Australia. Abstract and poster presentation PDB63 at the 16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, 2013.
  • Norrbacka K, Valentine W, Boye K, Curtis B, Bae J, Timlin L, Pollock R, Smith-Palmer J, Hunt B, Kendall D. Economic models of diabetes mellitus: Are we making decisions on the best available evidence? Abstract and poster presentation 1161 at the European Association for the Study of Diabetes 49th Annual Meeting, Barcelona, 2013.
  • Pollock RF, Smith-Palmer J, Muduma G, Odeyemi I. Budget Impact of Switching from an Immediate-Release to a Prolonged-Release Formulation of Tacrolimus in Renal Transplant Recipients in the uk Based on Differences in Adherence. Abstract and poster presentation PUK6 at the 16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, 2013.
  • Pollock RF, Smith-Palmer J, Muduma G, Odeyemi I. An Analysis of the Cost of Switching Renal Transplant Patients from an Immediate-Release to a Prolonged-Release Formulation of Tacrolimus Based on Differences in Trough Concentration Variability in the United Kingdom. Abstract and poster presentation PUK8 at the 16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, 2013.

2012

  • Kappelgaard AM, Wisniewski T, Seitz L, Pollock R, Qian Y. Product wastage from modern human growth hormone administration devices: a laboratory analysis. Abstract and poster presentation P02-51 at the 6th International Congress of the GRS and IGF Society, Münich, 2012.
  • Kappelgaard AM, Wisniewski T, Seitz L, Pollock R, Qian Y. Evaluation of Product Wastage from Modern Human Growth Hormone Administration Devices. Abstract and poster presentation PMD81 at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, 2012.
  • Todorova L, González-Gálvez G, Pollock RF. Long-Term Evaluation of the Economic Impact of Reducing HbA1C by 1% in Type 2 Diabetes Patients in Mexico. Abstract and poster presentation PDB44 at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, 2012.
  • Roca P, Lamri L, Belhadj M, Pollock RF, Valentine WJ, Todorova L. Long-Term Evaluation of the Economic Impact of Reducing HbA1C by 1% in Type 2 Diabetes Patients in Algeria. Abstract and poster presentation PDB41 at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, 2012.
  • Varol N, Wilson B, Norrbacka K, Pollock R, Valentine W. Cost-Effectiveness of Adding Twice-Daily Exenatide to Basal Insulin in Patients With Type 2 Diabetes in Scotland. Abstract and poster presentation PDB37 at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, 2012.

2011

  • Pollock RF, Curtis B, Smith H, Valentine WJ. Estimating the Cost-Effectiveness of Premixed Analog Insulin Versus Long Acting Analog Basal Insulin and Premixed Human Insulin in the Management of Type 2 Diabetes: A Long Term Analysis in the United Kingdom. Abstract and poster presentation PDB55 at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington DC, 2011.
    • Abstract selected to be showcased in the President's Poster Session by the Scientific Sessions Meeting Planning Committee.
  • Pollock RF, Curtis B, Smith H, Valentine WJ. Estimating the Long−Term Cost−Effectiveness of Premixed Insulin Analogs Versus Long−Acting Analog Insulin in the US. Abstract and poster presentation 418−PP at the American Diabetes Association 71st Scientific Sessions, San Diego, 2011.
  • Pollock RF, Curtis B, Boye KS, Timlin L, Valentine WJ. Identifying Potential Drivers of Cost Savings With Insulin Administration Devices in Type 2 Diabetes in the United States. Abstract and poster presentation PMD11 at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, 2011.

2010

  • Pollock R, Valentine W, Thomsen TL, Nishimura H. Reduced Long-Term Costs and Cardiovascular Complications in Patients Initiated on Rapid-Acting Insulin Aspart Compared With Human Insulin. Abstract and poster presentation PDB31 at the 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Atlanta, 2010.

2009

  • Montañana CF, Pollock RF, Haglund M, Valentine WJ, Ericsson Å. En hälsoekonomisk jämförelse av insulin detemir och NPH vid intensifierad insulinbehandling vid typ 2-diabetes. (A health economic comparison of insulin detemir and NPH at intensified insulin treatment for type 2 diabetes). Abstract and poster presentation at the Svenska Läkaresällskapet Medicinska Riksstämman, Stockholm, 2009.
    • Abstract featured in Pharmaco­Economics & Outcomes News article “Insulin aspart looks good for T2DM in Japan”. October 2009; 589:4.
  • Pollock RF, Valentine WJ, Thomsen TL, Nishimura H. Use of rapid-acting insulin aspart reduces costs and cardiovascular complications in type 2 diabetes when compared with human insulin. Abstract and poster presentation 891 at the European Association for the Study of Diabetes 45th Annual Meeting, Vienna, 2009.
    • Follow-up work: Pollock RF, Valentine WJ, Thomsen TL, Nishimura H. Rapid-acting insulin aspart reduces cardiovascular complications and costs in type 2 diabetes when compared with human insulin. Abstract and poster presentation at the International Diabetes Federation 20th World Diabetes Congress, Montreal, 2009.
  • Sullivan SD, Pollock RF, Garrison LP, Rinde H, Kolberg JA. Long-Term Cost-Effectiveness of a Diabetes Risk Score. Abstract and oral presentation at the American Diabetes Association 69th Scientific Sessions, New Orleans, 2009.
  • Kim J, Pollock R, Jung S, Diamantopoulos A, Lees M. Cost-Effectiveness of Rivaroxaban Versus Enoxaparin for Prophylaxis After Total Hip or Total Knee Replacement in Korea. Abstract and poster presentation PCV38 at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, 2009.

Earlier

  • Invited SciComp@Cam talk on OS X Development and BioSAVE at the University of Cambridge Centre for Mathematical Sciences in October 2007.

Education

Computing skills

  • Highly proficient at programming in Objective-C, Java, JavaScript, PHP (including Symfony and Doctrine), Python and Visual Basic for Applications
  • Thorough working knowledge of JavaScript, HTML5, CSS 3, XML and XSLT
  • Deep familiarity with Microsoft Word, Excel and PowerPoint
  • Experienced with Windows, Mac OS X and OpenBSD UNIX
  • Excellent knowledge of UNIX utilities and system administration

Distinctions

  • Final year master's project came top-in-year (85%)
  • Third-year essay on the physiological, pathological and biochemical effects of excessive alcohol consumption came second-in-year (83%)
  • Winner of Trinity College Science Essay Prize 2005

Other achievements

  • Duke of Edinburgh Gold Award
  • Millennium Volunteers Award of Excellence
  • ABRSM Grade 8 on piano and violin